Show an ad over header. AMP

I am the FIRST

COVID lab-leak debate intensifies scrutiny of virus experiments

The controversy over the origin of the COVID-19 virus is renewing focus on how the risks and benefits of pathogen-altering experiments are weighed and managed.

Why it matters: Better governance of biorisks would limit the threat of a human-made pandemic — and could help identify the origin of future outbreaks more quickly and with a lot less controversy.


What's happening: There's no conclusive evidence to support the idea that SARS-CoV-2 emerged from a lab accident, but the possibility is spurring debate about the risks of some biological research and guardrails for gain-of-function research.

  • In some of that research — but not all — scientists enhance viruses to make them more transmissible or more lethal, arguing it can provide insights about the pandemic potential of a pathogen.
  • But the scope of gain-of-function research isn't sharply defined and can encompass a wide range of experiments.

Where it stands: The current framework for oversight in the U.S. is limited to federally funded research and doesn't cover the increasingly larger role the private sector plays, says Anita Cicero, deputy director of the Center for Health Security at Johns Hopkins University — nor does that oversight extend overseas.

  • "There are big gaps between what some countries are doing, and there is some international guidance, but it is very much up to individual countries and labs to have their own policies," says Gregory Koblentz of the Center for Security Policy Studies at George Mason University, who recently published a report about maximum biosafety labs around the world.

What they're saying: Some experts have called for an outright ban of pathogen-enhancing research, but others argue it can continue to be done in safe and more transparent ways.

  • On the one hand, there are concerns that new rules or regulations based on a vague definition of gain-of-function research could hamper the scientific process and the development of countermeasures against emerging viruses, says Koblentz. Such studies have yet to be definitively linked to any outbreak.

But some researchers question the stated benefits of some gain-of-function experiments.

  • Studies that turn animal viruses that aren't transmissible or pathogenic in humans into novel ones that have those properties have "almost no value in terms of predicting pandemics and have extreme risks because their entire scientific validity rests on creating something that's inherently dangerous," Harvard epidemiologist Marc Lipsitch said earlier this week at a Brookings Institution event.
  • There's a need to make sure "scientists are taking appropriate safeguards against those risks, that research has some defined benefit worth the risk, and that there is a degree of transparency and oversight so we know there is a system weighing those benefits and risks," says Koblentz.

How it works: Right now, the risk-benefit assessment for individual studies in the U.S. largely falls to internal review boards of experts at universities, laboratories and federal agencies that evaluate proposed research and enforce federal guidelines.

  • Cicero says those boards need "more tools to evaluate the actual benefits and whether there are alternative methods of learning the same thing but with lower risk."

And there are calls for more transparency in the review process, which isn't public in the name of protecting scientific methods and intellectual property.

  • "If you want to work in a field where you are creating risks at the population level, you should be willing to do it in a way that is open enough so that people can evaluate those risks," Lipsitch said at the event.
  • But other experts say revealing some aspects of the process could be counterproductive.

The big picture: Pathogen-enhancing research is just one part of the overall risk picture of some biological science.

  • One hypothesis about the potential origin of SARS-CoV-2 is that the virus had been collected from animals in the wild and was being studied without being enhanced before researchers became infected with it.
  • Some experts propose improving tracking of laboratory-acquired infections and physically isolating the location of labs conducting experiments that carry higher risks. (Wuhan in China, for example, has a population greater than 11 million, larger than any city in the U.S.)
  • "If it came from nature, you have to decide whether you're going to continue to collect these viruses and bring them back to laboratories," says Steven Quay, a biotech entrepreneur who has studied the possibility of a COVID lab leak. "If it came from gain-of-function, you need to control that."

What to watch... what role the World Health Organization and other entities may take in developing international guidelines around governing pathogen-enhancing research, which could potentially mirror the emerging frameworks for human genome editing.

  • Another approach is that labs could accept third-party inspections by experts who evaluate their practices for mitigating biorisks and provide recommendations for strengthening them, says Koblentz.

The bottom line: Whatever the ultimate cause of the COVID-19 pandemic was — and we may never know — it's reasonable to take steps to better govern research that could go wrong.

4 ffp

Why the startup world needs to ditch "unicorns" for "dragons"

When Aileen Lee originally coined the term "unicorn" in late 2013, she was describing the 39 "U.S.-based software companies started since 2003 and valued at over $1 billion by public or private market investors."

Flashback: It got redefined in early 2015 by yours truly and Erin Griffith, in a cover story for Fortune, as any privately-held startup valued at $1 billion or more. At the time, we counted 80 of them.

Keep reading... Show less

Scoop: Facebook's new moves to lower News Feed's political volume

Facebook plans to announce that it will de-emphasize political posts and current events content in the News Feed based on negative user feedback, Axios has learned. It also plans to expand tests to limit the amount of political content that people see in their News Feeds to more countries outside of the U.S.

Why it matters: The changes could reduce traffic to some news publishers, particularly companies that post a lot of political content.

Keep reading... Show less

Scoop: Amazon quietly getting into live audio business

Amazon is investing heavily in a new live audio feature that's similar to other live audio offerings like Clubhouse, Twitter Spaces and Spotify's new live audio platform, sources tell Axios.

Why it matters: As with Amazon's efforts in podcasting and music subscriptions, the company sees live audio as a way to bolster the types of content it can offer through its voice assistant, Alexa, and its smart speaker products.

Keep reading... Show less

Hurricane Ida exposes America's precarious energy infrastructure

The powerful hurricane that plunged New Orleans into darkness for what could be weeks is the latest sign that U.S. power systems are not ready for a warmer, more volatile world.

The big picture: “Our current infrastructure is not adequate when it comes to these kinds of weather extremes,” Joshua Rhodes, a University of Texas energy expert, tells Axios.

Keep reading... Show less

"We must go further": 70% of adults in European Union are fully vaccinated

About 70% of adults in the European Union are fully vaccinated against COVID-19, Ursula von der Leyen, the president of the European Commission, said Tuesday.

Why it matters: The milestone makes the E.U. one of the world's leaders in inoculations, after an initially lagging vaccine campaign, the New York Times notes.

Keep reading... Show less

What Elizabeth Holmes jurors will be asked ahead of fraud trial

Jury selection begins today in USA v. Elizabeth Holmes, with the actual jury trial to get underway on Sept. 8.

Why it matters: Theranos was the biggest fraud in Silicon Valley history, putting both hundreds of millions of dollars and thousands of patients' health at risk.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories